All posts
-
PODCAST: Inside the UK CAA’s eVTOL Delivery Model with Darryl Abelscroft
Our newest podcast episode is real-time! Today, we were happy to be signed up with by Darryl Abelscroft, that operates in the Future Safety And Security and Development Department …
-
South32 backs $35M push at Alaska Arctic copper project
Australia’s South32 (ASX, LON, JSE: S32) is proceeding with an enthusiastic strategy to progress the copper-rich Arctic down payment in north-western Alaska with its 50:50 jo…
-
AI helps supply chain start-ups raise capital
Supply chain startups looking for funding would certainly succeed to profile themselves in the area of expert system (AI). “Some financiers are just placing cash right into s…
-
South32 targeting Arctic project in Alaska with joint venture partner
Johannesburg Supply Exchange-listed South32 is targeting the copper-dominant Arctic task in the Ambler mining area of north-western Alaska with its Canada-based 50:50 joint endeavo…
-
Listed Danish biotech company fights for survival after FDA rejection and failed capital raising
IO Biotech, which has significant Danish structures amongst its proprietors, is currently discovering tactical chances to make it through as a firm.
-
New Novo agreement part of plan to drop special research area
The brand-new contract with Canadian companion Facet Biosystems creates component of Novo Nordisk’s leave from cell treatment research study.
-
Novo Nordisk launches crucial trial with weight loss hope
According to an expert at AL Sydbank, Amycretin, which will certainly currently be checked in stage III tests, is among one of the most vital prospects in Novo Nordisk’s late…
-
Johnson & Johnson’s Darzalex sales exceed expectations
The cancer cells medication Darzalex, where Genmab obtains aristocracies, produced sales of USD 3,903 m in the 4th quarter of the year.
-
Competition intensifies in the peanut allergy market – analysts see opportunity for ALK
With a solid American concentrate on peanut allergic reactions, ALK might accomplish its long-awaited innovation in the United States if the firm’s injection prospect verifie…
-
Leo Pharma launches Phase 3 trial of growth hope Anzupgo
As part of efforts to expand Anzupgo into additional disease areas, LEO Pharma has launched a new phase 3 trial. The drug “has the potential to become our biggest product,” the com…
